• 00D
  • 00H
  • 00M
  • 00S
Register Now
Search

UroGP 2023

2023 Program

THE LATEST UROLOGY IN GENERAL PRACTICE INSIGHTS

*Please note, program is subject to change

UroGP 2024
0755 - 0800
Welcome by conveners
Prof Damien Bolton & Prof Nathan Lawrentschuk
0800 - 0820
New medical therapies in BPH for the GP
Dr Renu Eapen
0820 - 0840
Surgical treatment options for BPH and the post-operative care in the community and Q&A
Prof Damien Bolton
0840 - 0900
PSA testing: who needs what test and when?
Dr Anthony Ta
0900 - 0915
Demystifying prostate MRIs - case presentations
Mr Bradley Newell
0915 - 0930
Active surveillance in prostate cancer – GP involvement and role
Prof Nathan Lawrentschuk
0930 - 950
Urological dermatology for the GP; A Case-by-case Evaluation Scenario
Dr Isaac Lee
0950 - 1015
Morning tea with industry
1015 - 1030
Testicular Cancer – Red Flags and What To Do?
Mr Dixion Woon
1030 - 1045
Haematuria workup in the community: what investigations to order and when? Case analyses with GP participation
Mr Peter Liodakis
1045 - 1105
Kidney lesions – which ones need what treatment?
Mr Yee Chan
1105 - 1125
New urological therapies seen in the community: Discussion and quiz
A/Prof Joseph Ischia
1125 - 1140
GP led management of urinary stones – case-based discussions
Mr Greg Jack
1140 - 1155
Bladder cancer and GP involvement: interactive discussion
Prof Nathan Lawrentschuk
1155 - 1210
Radiation therapy for GP’s: understanding the basics
Prof Michael Chao
1210 - 1230
Bladder Cancer and the GP involvement: Case Presentations and Interactive Discussion
Prof Nathan Lawrentschuk
1230 - 1300
Lunch with exhibitors
1300 - 1320
Physiotherapy for pelvic pain and incontinence: what it is and how to counsel your patients
Ms Tafy Saede
1320 - 1335
Medical therapies you can prescribe for incontinence
Dr Jos Jayarajan
1335 - 1350
Case discussion: GP led management of recurrent urinary tract infections?
Dr Sandra Elmer
1350 - 1410
Vasectomy and its reversal – tips on patient counselling
Mr Andrew Troy
1410 - 1430
Slings and Neuromodulation for Urinary Incontinence – Problems and Solutions?
A/Prof Johan Gani
1430 - 1450
Erectile dysfunction in General Practice
Dr Kapil Sethi
1450 - 1500
Final Question and Answer session plus Case examples
Prof Nathan Lawrentschuk
1500 - 1505
Closing remarks
Prof Damien Bolton & Prof Nathan Lawrentschuk
1505 - 1605
Research presentations in conjunction with YURO

2023 Sponsors and Exhibitors

Platinum Sponsor
Boston-Scientific_300x300.png
Gold Sponsor
GenesisCare_300x300.png
Silver Sponsors
AstraZeneca_300x300.png
UroGP_SponEx_300x300-6.png
Ipsen_300x300.png
UroGP23-Sponsor-Dorevitch.jpg
Mayne-Pharma-300x300-1.png
Mundipharma_300x300.png
Exhibitors
Abbvie-300x300-1.png
Astellas-300x300-1.png
UroGP_SponEx_300x300-6.png
Cipla_300x300.png
Device-Technologies_300x300-1.png
Ipsen_300x300.png
Mayne-Pharma-300x300-1.png
UroGP_SponEx_300x300-5.png
Karl-Storz-300x300-1.png
Palette-300x300-1.png
ABOUT
PROGRAM
SPONSORS & EXHIBITORS
MAILING LIST

Keep up to date with the latest from UroGP

Join mailing list

Copyright 2021-2024 © UroGP. All rights reserved.

Designed and built by MCI Australia

Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. We are anchored in our commitment to clinician education to support the evolving needs of the urological community. Boston Scientific offers a range of solutions for the treatment of kidney stones, benign prostatic hyperplasia (BPH), erectile dysfunction (ED), male incontinence and pelvic floor disorders.

GenesisCare

GenesisCare is an Australian based global company
We have more than 440 centres to help us bring the right care to our patients. For radiotherapy, that includes 14 centres in the UK, 21 in Spain, 36 in Australia and 300 in the U.S. We also offer cardiology and sleep services at more than 80 locations across Australia. Every year our team sees more than 400,000 people globally.

We work to develop detailed understanding of patient needs to design the right care plan whether being treated for cancer, heart disease or sleep disorders.

There are seven GenesisCare radiotherapy centres in the Melbourne Metro region.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory & Autoimmunity, Cardiovascular & Metabolic Disease and Oncology.

The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit: www.astrazeneca.com

Bayer

Bayer is a global life science company with expertise in healthcare and agriculture. Guided by our purpose, Science For A Better Life, Bayer has been making a positive difference to the lives of Australians since 1925. As people live longer and the population continues to grow, Bayer is one of the few companies that takes a comprehensive view of these issues. We apply our global scientific expertise in healthcare and agriculture to deliver innovations locally to help people and the planet thrive.

Approval number: PP-NUB-AU-0101-1
Date of preparation: August 2021

Ipsen

Ipsen provides specialty medicines and quality services to Healthcare Professional and their patients suffering from debilitating diseases.

At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. We deliver tailored solutions through our agility and innovation and we strive to be even better tomorrow than we are today.

Ipsen Pty Ltd is the Australian affiliate of a global biotech company.

Mayne Pharma

Mayne Pharma offers two Urology products in Australia: 

Urorec® (silodosin)- highly selective alpha blocker for relief of lower urinary tracts symptoms associated with BPH. 

Monurol® (fosfomycin trometamol)- single dose oral antibiotic approved for treatment of uncomplicated lower UTI in females over 12 years. 

Contact diana.krasnopeeva@maynepharma.com or au.enquiries@maynepharma.com 

Mundipharma

Mundipharma is a healthcare company that provides healthcare products to Australians to enable them to live well and age well. We improve patients’ lives in meaningful ways by providing effective therapies along with educational resources that support their proper use. Mundipharma Australia is a member of a global network of independent associated companies which are engaged in research, development, production and marketing of prescription medicines and healthcare products. Our areas of expertise in ethical medicine include pain, oncology, respiratory disease, and ophthalmology.

AbbVie

AbbVie is a global biopharmaceutical company committed to developing innovative therapies for some of the world’s most complex conditions. In Australia we employ more than 450 people with our therapies currently benefiting more than 40,000 Australians across several therapeutic areas: Immunology, Oncology, Virology, Neuroscience and Aesthetics.

Astellas

Astellas stands on the forefront of healthcare change, turning innovative science into VALUE for patients. Astellas is a global pharmaceutical company headquartered in Japan, with a team of more than 14,500 people in over 70 countries worldwide.*Making a positive impact on patients’ lives is the purpose behind everything we do. We focus our research and development on healthcare solutions that have the greatest potential to transform lives. We are relentless in our pursuit of scientific progress and in tackling unmet medical needs.  Our medicines are extending and enhancing quality of life for those living with conditions that have limited or no alternative treatment options. Our ‘Focus Area’ approach means that we approach drug discovery, research and development from multiple perspectives. At every level of Astellas, we put patients first to advance innovative early science into breakthrough treatments that can directly improve peoples’ lives. In Australia our local team draws on the strength, heritage and expertise of Astellas globally to help improve the health of patients across the country. Our culture of doing good for others and contributing to a sustainable society is underpinned by our core values of patient focus, ownership, results, openness and integrity.

CIPLA Australia

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Device Technologies

For over 25 years, Device Technologies has been pioneering possibility in the Australasian healthcare landscape – seeking out and bringing to market, some of the world’s most advanced healthcare products. From high-quality consumables to advanced theatre equipment and robotics, Device Technologies is Australasia’s largest independent provider of medical solutions and technologies. Partnering with the world’s most innovative medical companies, we offer a comprehensive range of supplies with client care at the core of our values. Our dedicated team of over 750 highly skilled healthcare specialists and support staff, is committed to providing superior outcomes for healthcare professionals and their patients across the entire healthcare community.

Seipel Group

Seipel Group Pty Ltd is an Australian company committed to the research and development of innovative formulations to improve urinary control at all life stages. Products include Urox®, Prorox® and Urox® Junior for the treatment of overactive bladder, male and female incontinence, bedwetting and chronic cystitis.

KARL STORZ

Since its beginnings in 1945, KARL STORZ Endoscopy has established itself as the market leader in the manufacturing and sale of endoscopic devices and cameras to hospitals worldwide. 

The KARL STORZ range of products for Urology includes the Flex Xc video ureteroscope for the treatment of stones,  C-View Video Cystoscope with a portable monitor for visualisation of the bladder at the bedside.  

KARL STORZ is also the proud manufacturer of an innovative camera platform known as Image 1s which combines three visualisation technologies: Clara, Chroma and Spectra A/B for diagnosis and treatment of bladder, kidney and ureteral tumours to give you the best endoscopic viewing experience. 

Palette Life Sciences

Palette Life Sciences is transforming applications of existing technologies to provide novel solutions for under-served conditions. 

The company’s portfolio of products in Australia includes Deflux for Vesico Ureteral Reflux (VUR) in children and, BARRIGEL, a bio-compatible injectable treatment for protection of the rectal wall when treating prostate cancer with radiation.  

Lumus Imaging

For many years, Healthcare Imaging Services have operated under multiple brand names across Australia to provide a variety of imaging services to our patients, referrers, suppliers, and partners. As we continue to support our aim to be a customer-centric healthcare business, we have unified all our Health Care Imaging Services brands under one national brand, Lumus Imaging®. Lumus Imaging harnesses all of our knowledge and expertise and combines it with the empathy and care of our people. 

In addition to refreshing our brand identity across our 135 site nationally, Lumus Imaging is updating services, focusing on digital capabilities, and enhancing the way the business interacts with its patients and referrers. No matter where you are or what you need, at Lumus Imaging, we are here to provide you with the knowledge that matters by people that care.

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Facebook Twitter Linkedin Youtube Instagram